COMMUNIQUÉS West-GlobeNewswire

Annual General Meeting in Coloplast A/S - Election of own Chairman and Deputy Chairman
07/12/2017
See enclosed pdf.
Articles of Association for Coloplast A/S
07/12/2017
See enclosed pdf.
Annual General Meeting of Coloplast A/S
07/12/2017
The Annual General Meeting of Coloplast A/S has just been adjourned. See the report on transactions in the enclosed pdf. The report is attached in Danish and English.
Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology
07/12/2017
Presentation of Posters by Expert Scientists Now Available On-Demand on Crown Bioscience’s Website https://www.crownbio.com/eortc17-posters SANTA CLARA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a [...]
Hospitals Save Lives and Money by Investing in Climate Resilience
07/12/2017
BOSTON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- In the wake of costly storms and wildfires in 2017, health care leaders can safeguard lives and their organization's financial viability by investing in climate resilience, [...]
Exergen Reaches New Milestone: Temporal Artery Thermometers Now Used by More Nurses Than Any Other Type of Thermometer
07/12/2017
WATERTOWN, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- A recent survey reveals that over 50% of nurses in the U.S. use a temporal artery thermometer professionally - more than oral (48%), rectal (13%), axillary (23%), and [...]
Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians
07/12/2017
NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet) , a wholly-owned subsidiary of the Medical Society of Delaware (MSD) , has awarded a [...]
Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
07/12/2017
Company announcement - No. 55/2017 Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes First patient recruited in the second Phase 3 clinical trial [...]
Cannabix Technologies Inc. Closes $4.6 Million Bought Deal Private Placement and $977,500 Concurrent Non-Brokered Private Placement
07/12/2017
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (the “Company”) is pleased to [...]
CohBar Announces the Appointment of Dr. John Amatruda to its Board
07/12/2017
MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related [...]
INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis
07/12/2017
PHOENIX, Dec. 07, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ) (“INSYS” or “the company”), announced today that it has started a proof-of-concept study of two formulations of epinephrine nasal spray [...]
The Ensign Group, Inc. Increases Quarterly Dividend to $0.045 Per Share
07/12/2017
MISSION VIEJO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG ), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]
Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition
07/12/2017
Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by [...]
XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc.
07/12/2017
Expands portfolio of partner-funded programs $240 million in potential milestone payments Royalties ranging from the high single-digits to mid-teens on net sales Beyond XOMA 358, XOMA adds three additional programs to [...]
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
07/12/2017
LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]
Yield10 Bioscience CSO Dr. Kristi Snell to Present at CanolaWeek 2017
07/12/2017
WOBURN, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN ) announced that CSO Kristi Snell, Ph.D., will be presenting today on a panel being held at the CanolaWeek 2017 conference. Dr. [...]
Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team
07/12/2017
SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V: KALY ) and (OTCQB:KALTF) (the " Company " or " Kalytera ") today announced the initiation of a Phase 2 clinical [...]
Gala Global Inc. Announces Name Change and Shift in Business Strategy
07/12/2017
IRVINE, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTCBB: GLAG ) announces its filing a name change to Gala Pharmaceuticals Inc. The name change more closely aligns Gala Pharmaceuticals Inc., (GPI) to [...]
Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash
07/12/2017
PLYMOUTH, Minn., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL ) announced today a definitive merger agreement by which Stryker Corporation (NYSE: SYK ) will acquire Entellus in an all cash [...]

Pages